Date：21 July (Wednesday)
Time: 12:20 – 13:50 (GMT+8)
Dr. Justin Chin is the Company President of AstraZeneca Taiwan, a global research-based pharmaceutical company, focused on Oncology, Cardiovascular, Renal, Metabolism and Respiratory diseases. He is also Standing Director of IRPMA; and Board Governor and Pharmaceutical Committee Co-Chair of AmCham Taiwan. He has more than 20 years of experience in the healthcare industry and has worked in Singapore, USA, China, Philippines and Taiwan. He is also a medical doctor with a background in public health.
AstraZeneca is a science-led biopharmaceutical company investing nearly 25 % of its total revenue in R&D, delivering a strong pipeline of new medicines. Our main R&D sites are based in Gaithersburg, US; Gothenburg, Sweden; and Cambridge, UK.
Accelerating innovation lies at the core of AstraZeneca. Our global A.Catalyst network activates partnerships around the world for biomedical innovation – each hub contributes to our patient-centric goals by addressing unique unmet needs. As part of this network, AstraZeneca Taiwan supports Taiwan’s start-ups and promotes biomedical industry development in Taiwan.